Please login to the form below

Not currently logged in

Life sciences sector 'aggressively embracing' new technology

Technology-driven approaches drive breakthroughs, says a new study

IMS Institute for Healthcare Informatics reportThe use of cloud-based applications, embedded analytics and integrated systems is cutting costs and improving patient outcomes, according to a new report.

The IMS Institute for Healthcare Informatics also found life sciences companies are 'aggressively embracing' new technology-driven approaches.

This technology wave has the potential to drive transformational change over the next three years in overall healthcare system efficiency and the effectiveness of treatments, said the organisation.

The study, Riding the Information Technology Wave in Life Sciences: Priorities, Pitfalls and Promise, found life sciences companies shifting their technology-based approaches to align cross-functional activities, optimise their organisations and improve the effectiveness and agility of commercial teams.

The study asked decision makers in IT, marketing, sales, operations and management from 70 life sciences organisations about their current and planned use of new IT solutions and among its conclusions were that new investment is focusing on enabling greater patient engagement.

Overall, respondents expect continued cost reductions across the industry, and 40 per cent pointed to planned cuts of more than 10 per cent over the next three years. In addition, 74 per cent of participants want greater value from healthcare information such as electronic medical records (EMR) and other real-world data.

21st March 2014

From: Research, Sales, Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...